Oncology (Williston Park). 2020 Jan 15;34(1):20.
Multiple studies designed to evaluate chimeric antigen receptor (CAR) T-cell therapies in various hematologic malignancies appeared to show promise at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida.
在佛罗里达州奥兰多举行的第 61 届美国血液学会 (ASH) 年会和博览会上,多项旨在评估嵌合抗原受体 (CAR) T 细胞疗法在各种血液恶性肿瘤中的疗效的研究似乎显示出了希望。